(Total Views: 532)
Posted On: 05/05/2022 7:04:35 AM
Post# of 9144
in my update ( year end), I saw this concerning trading
“ 3) After discussions with the OTC, and determining they will not accept independent SEC filings in order to restore NanoLogix to tradable Pink Sheet status, we will begin providing OTC with financials, and accept the burden of a $10,000 yearly fee. This is required to restore the Company to tradable status.”
Nothing was mentioned about how the money would be raised to restore nnlx to trading status or where the money would come from for this. I think this was approximately 6k
“ 2) We are also preparing for FDA Registration in January 2022 in order to be authorized to sell to laboratories and other groups that use Petri plates for testing samples under FDA regulated conditions. The FDA registration will list the FlatPack, our currently produced product, along with the ELISA variants of the N-Assay and RVA technologies.“
The mention of raising money was solely directed towards testing RVA under heading “ An Exciting and Vital Development”
“ 3) After discussions with the OTC, and determining they will not accept independent SEC filings in order to restore NanoLogix to tradable Pink Sheet status, we will begin providing OTC with financials, and accept the burden of a $10,000 yearly fee. This is required to restore the Company to tradable status.”
Nothing was mentioned about how the money would be raised to restore nnlx to trading status or where the money would come from for this. I think this was approximately 6k
“ 2) We are also preparing for FDA Registration in January 2022 in order to be authorized to sell to laboratories and other groups that use Petri plates for testing samples under FDA regulated conditions. The FDA registration will list the FlatPack, our currently produced product, along with the ELISA variants of the N-Assay and RVA technologies.“
The mention of raising money was solely directed towards testing RVA under heading “ An Exciting and Vital Development”
(0)
(0)
